MIMEDX Expects Adjusted EBITDA to Be Approximately Breakeven
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Consensus $314.38M. Adjusted EBITDA is expected to be approximately breakeven on a full year basis. "While some disruption was expected, the challenges we are now seeing in the market, coupled with irrational behavior by some industry participants, has added complexity that could not have been anticipated. To compound matters, the wound care market is adjusting to the new reimbursement rules at an extremely slow pace. We are working closely with our customers to help them adapt to the changes. Importantly, as we exited the quarter, we saw promising signs of volume recovery in Wound Care Centers and Hospitals. On the other side of this transition, we will be competing in a far more attractive space and believe MIMEDX is uniquely positioned to lead the market. Our Surgical franchise continues to post double-digit top-line growth, with 50% growth over the past three years," concluded Capper.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDXG
Wall Street analysts forecast MDXG stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.780
Low
10.00
Averages
11.75
High
13.00
Current: 3.780
Low
10.00
Averages
11.75
High
13.00
About MDXG
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MiMedx Group Under Investigation for Securities Fraud
- Financial Performance Decline: MiMedx reported a non-GAAP earnings per share of -$0.05 for Q1 2026, missing consensus estimates by $0.01, with revenue of $59 million reflecting a 33.1% year-over-year decrease, indicating severe financial pressure that could impact future funding capabilities.
- Negative Market Reaction: Following the earnings report, MiMedx's stock price fell by $0.32, or 9.26%, closing at $3.09 per share, reflecting investor concerns about the company's future prospects and potentially leading to liquidity issues.
- Impact of Medical Policies: CEO Joseph H. Capper noted that new Medicare reimbursement policies implemented at the start of the year caused significant confusion in the wound care sector, directly affecting sales expectations and forcing the company to lower its full-year 2026 net sales forecast to a range of $260 to $290 million.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether MiMedx and its executives have engaged in securities fraud or other unlawful business practices, which could lead to legal liabilities for the company and further exacerbate investor anxiety.
See More
MiMedx Group Under Investigation for Securities Fraud
- Financial Performance Decline: MiMedx reported a non-GAAP earnings per share of -$0.05 for Q1 2026, missing consensus estimates by $0.01, with revenue of $59 million falling short by $6.8 million and reflecting a 33.1% year-over-year decrease, indicating severe market challenges for the company.
- Market Impact Factors: CEO Joseph H. Capper noted that new Medicare reimbursement policies took effect at the beginning of the year, causing significant confusion across nearly all care settings, which adversely impacted Q1 performance, highlighting the direct impact of policy changes on company operations.
- Sales Forecast Downgrade: Due to disruptions in the wound care market, MiMedx lowered its full-year 2026 net sales expectations to a range of $260 to $290 million, indicating weakened confidence in future performance, which may affect investor sentiment and stock price.
- Stock Price Reaction: Following the earnings report, MiMedx's stock price fell by $0.32, or 9.26%, closing at $3.09 per share, reflecting market concerns over the company's financial health and potentially leading to further investor withdrawals.
See More
MiMedx Group Under Investigation for Securities Fraud
- Financial Performance Decline: MiMedx reported a non-GAAP earnings per share of -$0.05 for Q1 2026, missing consensus estimates by $0.01, with revenue of $59 million falling short by $6.8 million and representing a 33.1% year-over-year decrease, indicating significant market challenges for the company.
- Market Impact Factors: CEO Joseph H. Capper highlighted that new Medicare reimbursement policies implemented at the start of 2026 caused substantial confusion in the advanced wound care sector, leading to significant business disruptions across various care settings that adversely affected overall performance.
- Sales Forecast Revision: Due to the disruptions in the wound care market, MiMedx has lowered its full-year 2026 net sales expectations to a range of $260 to $290 million, reflecting a cautious outlook that may impact investor confidence moving forward.
- Stock Price Reaction: Following the earnings report, MiMedx's stock price fell by $0.32, or 9.26%, closing at $3.09 per share, which underscores market concerns regarding the company's financial health and future prospects.
See More
TELA Bio Announces Board Refreshment Plan for Growth
- Board Refreshment Plan: TELA Bio announced a board refreshment plan post the 2026 Annual Meeting, where four current directors will step down to make way for four new directors with deep expertise in medtech commercialization, financial strategy, and corporate turnarounds, aimed at supporting the company's commercial growth and operational excellence.
- New Directors' Background: The new directors include Joseph Capper, who brings nearly 30 years of experience in medtech and successfully led BioTelemetry, Inc. through a turnaround that culminated in its $2.8 billion acquisition by Royal Philips, showcasing his capability in value creation.
- First Quarter Revenue Forecast: The company anticipates first-quarter 2026 revenue of approximately $19 million, exceeding previous guidance of $18.5 million, reflecting strong market performance and growth potential, although final results will be reported on May 12.
- Strategic Objectives: The addition of new directors will provide TELA Bio with extensive industry experience to optimize commercial organizations, enhance operational efficiency, and advance towards sustainable profitability and shareholder value creation, marking a significant shift in the company's strategic direction.
See More
MiMedx Group Reports Q1 2026 Earnings with Mixed Results
- Financial Performance Overview: MiMedx reported Q1 2026 net sales of $59 million, a 33% decline year-over-year, with surgical sales up 13% while wound care sales plummeted 60%, indicating significant market volatility and a shift in business structure.
- Market Dynamics Shift: CEO Capper highlighted that changes in Medicare skin substitutes have reset the market, with revised full-year net sales expectations now ranging from $260 million to $290 million, reflecting the company's cautious outlook on future revenues.
- Cost Structure Adjustments: CFO Rice noted that the restructuring is expected to yield annual savings of approximately $40 million, although this will incur a one-time charge of about $4 million in Q2, demonstrating the company's flexibility in addressing market challenges.
- Share Repurchase Plan: The company has received board authorization to initiate a $100 million share repurchase program, indicating management's confidence in future business recovery despite current pressures in the wound care market.
See More
MiMedx Group Q1 Earnings Announcement Scheduled
- Earnings Announcement Schedule: MiMedx Group (MDXG) is set to announce its Q1 earnings on April 29th after market close, with a consensus EPS estimate of -$0.04, reflecting a significant year-over-year decline of 166.7%, indicating substantial profitability challenges.
- Revenue Decline Expectations: The revenue estimate for Q1 stands at $65.8 million, representing a 25.4% year-over-year decrease, which highlights the company's struggles amid competitive pressures and weak demand, potentially impacting investor confidence moving forward.
- Historical Performance Review: Over the past two years, MDXG has beaten EPS estimates 75% of the time and revenue estimates 88% of the time; however, recent downward revisions in both EPS and revenue forecasts suggest growing concerns about the company's future performance.
- Revision Trend Analysis: In the last three months, there have been no upward revisions for EPS estimates, with two downward adjustments, while revenue estimates have seen five downward revisions, indicating a weakening analyst outlook that could adversely affect stock performance.
See More
MiMedx Group Under Investigation for Securities Fraud
- Financial Performance Decline: MiMedx reported a non-GAAP earnings per share of -$0.05 for Q1 2026, missing consensus estimates by $0.01, with revenue of $59 million reflecting a 33.1% year-over-year decrease, indicating severe financial pressure that could impact future funding capabilities.
- Negative Market Reaction: Following the earnings report, MiMedx's stock price fell by $0.32, or 9.26%, closing at $3.09 per share, reflecting investor concerns about the company's future prospects and potentially leading to liquidity issues.
- Impact of Medical Policies: CEO Joseph H. Capper noted that new Medicare reimbursement policies implemented at the start of the year caused significant confusion in the wound care sector, directly affecting sales expectations and forcing the company to lower its full-year 2026 net sales forecast to a range of $260 to $290 million.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether MiMedx and its executives have engaged in securities fraud or other unlawful business practices, which could lead to legal liabilities for the company and further exacerbate investor anxiety.
See More
MiMedx Group Under Investigation for Securities Fraud
- Financial Performance Decline: MiMedx reported a non-GAAP earnings per share of -$0.05 for Q1 2026, missing consensus estimates by $0.01, with revenue of $59 million falling short by $6.8 million and reflecting a 33.1% year-over-year decrease, indicating severe market challenges for the company.
- Market Impact Factors: CEO Joseph H. Capper noted that new Medicare reimbursement policies took effect at the beginning of the year, causing significant confusion across nearly all care settings, which adversely impacted Q1 performance, highlighting the direct impact of policy changes on company operations.
- Sales Forecast Downgrade: Due to disruptions in the wound care market, MiMedx lowered its full-year 2026 net sales expectations to a range of $260 to $290 million, indicating weakened confidence in future performance, which may affect investor sentiment and stock price.
- Stock Price Reaction: Following the earnings report, MiMedx's stock price fell by $0.32, or 9.26%, closing at $3.09 per share, reflecting market concerns over the company's financial health and potentially leading to further investor withdrawals.
See More
MiMedx Group Under Investigation for Securities Fraud
- Financial Performance Decline: MiMedx reported a non-GAAP earnings per share of -$0.05 for Q1 2026, missing consensus estimates by $0.01, with revenue of $59 million falling short by $6.8 million and representing a 33.1% year-over-year decrease, indicating significant market challenges for the company.
- Market Impact Factors: CEO Joseph H. Capper highlighted that new Medicare reimbursement policies implemented at the start of 2026 caused substantial confusion in the advanced wound care sector, leading to significant business disruptions across various care settings that adversely affected overall performance.
- Sales Forecast Revision: Due to the disruptions in the wound care market, MiMedx has lowered its full-year 2026 net sales expectations to a range of $260 to $290 million, reflecting a cautious outlook that may impact investor confidence moving forward.
- Stock Price Reaction: Following the earnings report, MiMedx's stock price fell by $0.32, or 9.26%, closing at $3.09 per share, which underscores market concerns regarding the company's financial health and future prospects.
See More
TELA Bio Announces Board Refreshment Plan for Growth
- Board Refreshment Plan: TELA Bio announced a board refreshment plan post the 2026 Annual Meeting, where four current directors will step down to make way for four new directors with deep expertise in medtech commercialization, financial strategy, and corporate turnarounds, aimed at supporting the company's commercial growth and operational excellence.
- New Directors' Background: The new directors include Joseph Capper, who brings nearly 30 years of experience in medtech and successfully led BioTelemetry, Inc. through a turnaround that culminated in its $2.8 billion acquisition by Royal Philips, showcasing his capability in value creation.
- First Quarter Revenue Forecast: The company anticipates first-quarter 2026 revenue of approximately $19 million, exceeding previous guidance of $18.5 million, reflecting strong market performance and growth potential, although final results will be reported on May 12.
- Strategic Objectives: The addition of new directors will provide TELA Bio with extensive industry experience to optimize commercial organizations, enhance operational efficiency, and advance towards sustainable profitability and shareholder value creation, marking a significant shift in the company's strategic direction.
See More
MiMedx Group Reports Q1 2026 Earnings with Mixed Results
- Financial Performance Overview: MiMedx reported Q1 2026 net sales of $59 million, a 33% decline year-over-year, with surgical sales up 13% while wound care sales plummeted 60%, indicating significant market volatility and a shift in business structure.
- Market Dynamics Shift: CEO Capper highlighted that changes in Medicare skin substitutes have reset the market, with revised full-year net sales expectations now ranging from $260 million to $290 million, reflecting the company's cautious outlook on future revenues.
- Cost Structure Adjustments: CFO Rice noted that the restructuring is expected to yield annual savings of approximately $40 million, although this will incur a one-time charge of about $4 million in Q2, demonstrating the company's flexibility in addressing market challenges.
- Share Repurchase Plan: The company has received board authorization to initiate a $100 million share repurchase program, indicating management's confidence in future business recovery despite current pressures in the wound care market.
See More
MiMedx Group Q1 Earnings Announcement Scheduled
- Earnings Announcement Schedule: MiMedx Group (MDXG) is set to announce its Q1 earnings on April 29th after market close, with a consensus EPS estimate of -$0.04, reflecting a significant year-over-year decline of 166.7%, indicating substantial profitability challenges.
- Revenue Decline Expectations: The revenue estimate for Q1 stands at $65.8 million, representing a 25.4% year-over-year decrease, which highlights the company's struggles amid competitive pressures and weak demand, potentially impacting investor confidence moving forward.
- Historical Performance Review: Over the past two years, MDXG has beaten EPS estimates 75% of the time and revenue estimates 88% of the time; however, recent downward revisions in both EPS and revenue forecasts suggest growing concerns about the company's future performance.
- Revision Trend Analysis: In the last three months, there have been no upward revisions for EPS estimates, with two downward adjustments, while revenue estimates have seen five downward revisions, indicating a weakening analyst outlook that could adversely affect stock performance.
See More
